2seventy bio, Inc.
TSVT evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Lead Asset:
- abecma (Approved)
What it means
What to watch
Prepared research question
What matters most for TSVT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
abecma (Approved)
Next Catalyst
—
Tracking 3 pipeline candidates for 2seventy bio, Inc..
Run 2seventy bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available 2seventy bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is 2seventy bio, Inc.'s lead drug candidate?
2seventy bio, Inc.'s most advanced tracked candidate is abecma (Approved) for Multiple myeloma.
Who is the CEO of 2seventy bio, Inc.?
Chip Baird is the chief executive officer of 2seventy bio, Inc. (TSVT).
What therapeutic areas does 2seventy bio, Inc. focus on?
2seventy bio, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.